CCRT and aerobic exercise: a randomised controlled study of processing speed, cognitive flexibility, and serum BDNF expression in schizophrenia

Yuanyuan Dai1, Hongyan Ding1, Xiaozhi Wu2, Chunhua Xu1, Tingting Jiang1, Liang Ming1, Zhong Xia1, Chuanfu Song1, Hongxian Shen1,2, Wei Hao3,4, and Shucai Huang1,2

Background: Computerised cognitive remediation therapy (CCRT) and aerobic exercise are often used to rehabilitate social functioning in patients with schizophrenia. However, there is limited knowledge regarding the effects of CCRT combined with aerobic exercise on cognitive function and brain-derived neurotrophic factor (BDNF) levels in patients with schizophrenia and cognitive impairment. Ninety-six patients with schizophrenia and cognitive impairment were included in this study and randomly divided into control, aerobic exercise (AE), and CCRT with aerobic exercise (CAE) groups. Changes in processing speed and cognitive flexibility at week 8 were assessed using the Trail Making Test: Part A, the Brief Assessment of Cognition in Schizophrenia: Symbol Coding Test, and the Stroop Colour-Word Test. Positive and Negative Syndrome Scale (PANSS) scores and serum BDNF expression were determined as secondary outcomes. The CAE group showed significant improvements in terms of changes in processing speed and cognitive flexibility compared to the control and AE groups. The CAE group showed significant improvements in serum BDNF levels compared to the control group at week 8 (p < 0.05), but there was no significant difference in serum BDNF expression between the CAE group and AE group. In conclusion, 8-week CCRT combined with aerobic exercise may improve some cognitive performance and negative symptoms in patients with schizophrenia. Aerobic exercise may have an immediate effect on serum BDNF levels rather than cognitive function.

Schizophrenia (2022) 8:84; https://doi.org/10.1038/s41537-022-00297-x

INTRODUCTION

Cognitive impairment is a common symptom of schizophrenia. More specifically, cognitive impairment is considered to be the third symptom component of schizophrenia (in addition to negative and positive symptomology). This symptom component mainly involves obstacles within attention, memory, thinking, and information integration processes. Cognitive deficits severely undermine the long-term prognosis of patients with schizophrenia. More specifically, even if hallucinations, delusions, and other psychotic symptoms improve, these cognitive deficits will continue to hinder the patient’s recovery of social function; this will eventually lead to difficulties for the patient to return to society. Therefore, treatment of cognitive deficits in patients with schizophrenia is of great clinical significance.

Previous clinical research has shown that the amelioration of cognitive deficits via antipsychotic pharmacological treatments in patients with schizophrenia is currently extremely limited, and that the efficacy of other pharmacological drugs addressing these cognitive deficits also seems to be marginal.

In clinical practice, aerobic exercise is often used as an adjuvant therapy to improve cognitive, behavioural, and social functioning in patients with schizophrenia. Previous studies have reported that aerobic exercise may have a positive impact on working memory, motor speed, attention, and executive function. Structured physical exercise is considered to ameliorate psychiatric symptomology. For example, some studies have found that exercise may significantly improve the negative symptoms, including depressive symptoms, in patients with schizophrenia, and improve their social function and quality of life. Physical exercise may reduce the risk of physical diseases in schizophrenia patients by improving cardiopulmonary and metabolic functions, and previous studies have found that physical exercise may increase hippocampal volume and white matter integrity in patients with schizophrenia. It has also been reported that physical exercise is associated with higher levels of neurotrophic factors, larger grey and white matter volumes, and better cognitive abilities in patients with schizophrenia.

Currently, computerised cognitive remediation therapy (CCRT) is considered to have a definitive positive effect on the improvement of cognitive function in patients with schizophrenia, including with regard to attention, memory, and executive functioning. Brain-derived neurotrophic factor (BDNF) is widely distributed in the brain, plays an important role in the structure and function of neurons by catalysing the growth and reorganisation of dendritic spines.
spines in response to changes in neuronal function, and is of great significance to the maintenance and development of cognitive functions.\textsuperscript{22,23} Studies have found that serum BDNF levels in adult schizophrenia patients are usually lower than in normal controls.\textsuperscript{24-26} Moreover, some brain function defects may be related to the disturbance of the BDNF system seen in patients with schizophrenia, including a decreased number of BDNF-positive neurons and a lower level of BDNF in the cortex and hippocampus.\textsuperscript{27,28} In addition, research to date indicates that serum BDNF levels may be a potential biomarker for evaluating the effects of cognitive training.\textsuperscript{29} Limited evidence also shows that exercise training increases the expression of BDNF in the brain and peripheral blood, which may have a positive effect on cognitive function.\textsuperscript{30,31}

Therefore, this study aimed to explore the effects of CCRT and aerobic exercise on information processing speed, cognitive flexibility, and BDNF in patients with schizophrenia presenting with cognitive impairment.

**PATIENTS AND METHODS**

**Study design**

This was a longitudinal, randomised, single-blind trial conducted at the Fourth People's Hospital of Wuhu (Wuhu, China). This study was registered at the Chinese Clinical Trial Registry (ChiCTR2000035746).

**Study hypotheses**

Our primary hypothesis was that CCRT and aerobic exercise would improve brain information processing speed and cognitive flexibility in patients with schizophrenia. Our secondary hypothesis was that an improvement in cognitive performance would be accompanied by an increase in serum BDNF levels.

**Sample size**

Based on a similar study conducted in schizophrenia patients,\textsuperscript{31} we estimated a necessary sample size of 69 (23 per group) according to the superiority test formula

\[
 n = \frac{\sum_{i=1}^{k} \left( X_i - x_2 \right) \frac{S_i}{k}}{\sum_{i=1}^{k} \left( X_i - x_2 \right)^2 / k - 1},
\]

wherein \( k \) represents the number of groups, and \( X_i \) and \( S_i \) represent the mean value and standard deviation of each group, respectively, for multiple groups,\textsuperscript{32} with \( \alpha = 0.05, \beta = 0.20 \), and \( k = 3 \). Within our enrolment process, the sample size was increased by 30% in consideration of potential study dropouts; hence, at least 90 participants were required (30 per group). Ultimately, 96 participants were recruited through in-hospital advertising in this study.

**Participants and inclusion/exclusion criteria**

All participants were inpatients at the Fourth People's Hospital of Wuhu and met the following inclusion criteria: (1) age 18–55 years; (2) patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for schizophrenia, with a duration of diagnosis of >2 years; (3) hallucinations, delusions, and other positive psychotic symptoms had disappeared; (4) Montreal Cognitive Assessment (MoCA) score <26; and (5) more than 5 years of educational experience, with a certain level of language comprehension so as to ensure that the participants could understand and sign the informed consent form and follow the prompts to perform simple mouse operations. The exclusion criteria were as follows: (1) suffering from organic diseases that may affect cognitive function; (2) taking non-antipsychotic drugs that may affect cognition; and (3) definite organic or functional damage to the respiratory, circulatory, and motor systems.

**Randomisation**

A standard online randomisation programme was used to randomly assign participants to control, aerobic exercise (AE), or CCRT combined with aerobic exercise (CAE) groups after obtaining informed consent and checking for eligibility (http://www.randomization.com).

**Blinding**

The blinding principle was applied as much as possible in this study. Namely, the participants in the AE and CAE groups were mixed for the aerobic exercise interventions, and all guidance coaches (nurses) were unaware of the participants' groupings, all investigators in charge of cognitive evaluation and serum BDNF concentration detection were blinded to study group assignment, and the investigators supervising data monitoring and statistical analysis were also not informed as to the study group assignments. At the same time, we tried to incorporate objective cognitive test data as evaluation indicators in order to reduce the interference of subjective factors pertaining to both participants and researchers on the study results. The nature of the intervention meant that the participants could not be blinded to their intervention group assignment. However, they were required to keep their group assignment confidential from their raters and therapists.

**Intervention setting**

**Intervention as usual.** Clinical intervention continued for all study participants in accordance with the Chinese guidelines for the prevention and treatment of schizophrenia.\textsuperscript{34} Usual treatment included antipsychotic pharmacological treatment, psychological consultation, medical care, and behaviour modification.

**Aerobic exercise training.** The complete intervention duration of the aerobic exercise training and CCRT interventions was 8 weeks. Participants in the AE and CAE groups were provided 45-min sessions of aerobic exercise by qualified instructors from Monday to Friday. The aerobic physical exercise protocol was designed based on previous reports by Lin et al.\textsuperscript{35} and Erickson et al.\textsuperscript{36} with minor modifications: music warm-up exercise (10 min) and walking on a treadmill at a speed of 6–9 km/h (30 min) followed by cool-down stretching (5 min). Heart rate was monitored during the exercise sessions using a portable recorder so as to ensure that participants maintained a moderate-intensity exercise exertion level of 50–70% of their maximum heart rate.\textsuperscript{36} Blood pressure was recorded before and after training.

**CCRT training.** Eight weeks of CCRT training was provided in the CAE group. The CCRT system administered herein was developed according to the principles of Wykes and Reeder.\textsuperscript{37} This system consists of 30 exercise sequences that dynamically adjust the difficulty as the accuracy reaches 80%, and is administered within two 30-min sessions each week for a total of 8 weeks (i.e., 16 total sessions). This intervention was supervised by experienced therapists at a ratio of one therapist to five participants.

**Assessments and outcomes**

All clinical interviews were conducted by three licensed psychiatrists with MDs who had at least 5 years of clinical experience in psychiatry. The following clinical data were evaluated at baseline using self-developed questionnaires (week 0): demographic data, medical history, and clinical medications (including age, sex, education, duration of illness, accumulated duration of medication use, use of psychiatric drugs, and smoking); psychotic symptoms were evaluated using the Chinese version of the PANSS;\textsuperscript{38} and cognitive impairment screening was conducted using the Chinese version of the MoCA.
Processing speed was assessed using the Trail Making Test: Part A (TMT-A) and the Brief Assessment of Cognition in Schizophrenia: Symbol Coding Test (SCT)\(^3\). Cognitive flexibility was evaluated using the Stroop Colour-Word Test (SCWT; with scores based on the number of completed categories over 45 s)\(^4\). Serum BDNF concentrations were detected at baseline using standard methodology\(^5\). Evaluations of processing speed and cognitive flexibility and the detection of BDNF concentrations in serum were conducted by two researchers. The data were also scrutinised to identify out-of-range values; any such values were examined and discrepancies were corrected within the source files.

One-way analysis of variance (ANOVA) and \(\chi^2\) tests were used to compare continuous and categorical data among the three groups as appropriate. Nonparametric tests were used when the assumptions of normality and/or homogeneity of variance were violated. Repeated measures ANOVA was performed to analyse potential effects on outcomes, with the treatment group (aerobic exercise combined with CCRT, aerobic exercise, or control groups) considered as an intergroup factor and time (baseline, 4 weeks, 8 weeks, and 12 weeks) considered as an intragroup factor. Age, education, gender, disease duration, and baseline values of the outcome measure were treated as covariates. Post hoc multiple comparisons at different evaluation times were performed using the Bonferroni–Dunn test. Pearson’s correlation analysis was conducted to investigate relationships between the changes in cognitive and non-cognitive outcomes (i.e., serum BDNF level and PANSS score). For the two-tailed test, the level of statistical significance was set to \(p < 0.05\).

**RESULTS**

Ninety-six participants were eligible to participate in the trial. Of these, 14 individuals withdrew from the trial for personal reasons without undergoing CCRT or AE training (Control 1, CAE 6, AE 7). The reasons for withdrawal included (1) discharge before the trial started (CAE 1, AE 2); (2) worsened symptoms (Control 1, AE 1); (3) unwillingness to rush to the training room within the agreed-upon time (CAE 1; AE 2); (4) participants’ concern about not being able to complete computer operations (CAE 3); and (5) quitting without a specified reason (CAE 1; AE 2). A total of 82 participants were included in the final analysis based on the intention to treat principle.

**Demographic and clinical characteristics**

Detailed information on demographic and other clinical characteristics is shown in Table 1. There were no differences in age, sex, education, smoking, duration of schizophrenia, or antipsychotic use among the three groups. PANSS scores, TMT-A time, SCT scores, SCWT performance, and serum BDNF levels were similar among the three groups (Table 1).

**Treatment outcomes**

**Primary cognitive outcomes.** We found a statistically significant overall difference among the three groups in TMT-A time (\(F = 5.768, p = 0.005, \eta^2 = 0.127\)) and SCT scores (\(F = 5.148, p = 0.008, \eta^2 = 0.115\)) (Fig. 1A, B). Statistically significant time effects (TMT-A: \(F = 8.976, p < 0.001, \eta^2 = 0.102\); SCT: \(F = 15.783, p < 0.001, \eta^2 = 0.167\)) and time-by-group effects (TMT-A: \(F = 3.302, p = 0.004, \eta^2 = 0.077\); SCT: \(F = 4.183, p = 0.001, \eta^2 = 0.096\)) were also found with respect to processing speed. The changes in TMT-A (\(F = 7.937, p < 0.001, \eta^2 = 0.167\)) and SCT (\(F = 8.882, p < 0.001, \eta^2 = 0.184\)) from baseline to week 8 were significantly different among the three groups (Fig. 1A, B and Table 2). Post hoc analysis revealed that the CAE group showed significant improvement in the processing speed test at week 8 as compared with the AE (TMT-A: \(p = 0.04;\) SCT: \(p = 0.008\)) or control groups (TMT-A: \(p = 0.002;\) SCT: \(p < 0.001\)), and no significant difference was found between the AE and control groups in the change of TMT-A time or SCT scores at week 8.

**Secondary cognitive outcomes.** The changes in TMT-A (\(F = 3.51, p = 0.032, \eta^2 = 0.083\)) and SCT (\(F = 3.881, p = 0.025, \eta^2 = 0.089\)) from baseline to week 12 were significantly different among the three groups (Fig. 1A, B). Post hoc analysis revealed that the CAE group showed significant improvement in the processing speed test at week 12 as compared with the AE (TMT-A: \(p = 0.023;\) SCT: \(p = 0.025\)).
**Table 1.** Baseline demographic data, clinical variables and cognitive characteristics of patients in three groups (n = 82).

| Demographics | Control subjects (n = 31) | CAE subjects (n = 26) | AE subjects (n = 25) | F or χ² value | df | p value |
|--------------|---------------------------|-----------------------|----------------------|---------------|----|--------|
| Age (years)  | 44.06 (8.40)              | 41.50 (8.72)          | 41.40 (7.86)         | 0.947         | 2  | 0.392  |
| Years of education | 9.16 (2.72) | 10.00 (2.74) | 9.00 (3.16) | 0.917 | 2  | 0.404  |
| Gender (men/women) | 20/11     | 22/4                 | 20/5                 | 3.473         | 2  | 0.176  |
| Clinical variables |                      |                       |                      |               |    |        |
| Duration of Illness (months) | 236.61 (112.71) | 236.27 (147.55) | 202.24 (98.20) | 0.712 | 2  | 0.494  |
| Duration of taking antipsychotics (months) | 203.87 (116.96) | 161.62 (129.38) | 176.76 (101.13) | 0.981 | 2  | 0.379  |
| Type of antipsychotics (FGA/SGA) | 3/28     | 2/24                 | 3/22                 | 0.296         | 2  | 0.874  |
| Equivalent dose of chlorpromazine | 374.19 (97.36) | 357.69 (102.66) | 328.00 (96.91) | 1.524 | 2  | 0.224  |
| Smoking | 8 (25.81%) | 12.23 (2.41) | 10.84 (2.64) | 2.192 | 2  | 0.118  |
| PANSS positive score | 18.71 (4.16) | 19.04 (4.84) | 17.60 (3.82) | 0.791 | 2  | 0.457  |
| PANSS negative score | 33.87 (4.65) | 34.23 (6.26) | 35.96 (5.30) | 1.136 | 2  | 0.326  |
| Age (years)  | 44.06 (8.40)              | 41.50 (8.72)          | 41.40 (7.86)         | 0.947         | 2  | 0.392  |

Continuous variables are listed as mean (SD). 
AE aerobic exercise, CAE CCRT combined with aerobic exercise, FGA first-generation antipsychotics, SGA second-generation antipsychotics, PANSS Positive and Negative Syndrome Scale, BDNF brain-derived neurotrophic factor.

Fig. 1  Comparison of processing speed and serum BDNF (n = 82). A Changes of the Trail Making Test-A; B changes of the Symbol Coding Test; and C changes of BDNF level in serum. The results are expressed as mean ± SD. Differences between two groups were analysed using two-way ANOVA for repeated measures, and post hoc multiple comparisons at different endpoints were performed using Bonferroni–Dunn test. *p ≤ 0.05, **p ≤ 0.01, as compared with control group. BDNF brain-derived neurotrophic factor, AE aerobic exercise, CAE CCRT combined with aerobic exercise.

There was a statistically significant difference across the three groups in Stroop word test scores (F = 3.657, p = 0.030, η² = 0.085) and Stroop colour test scores (F = 5.300, p = 0.007, η² = 0.118) (Fig. 2A, B). Significant time effects (Stroop word test: F = 8.446, p < 0.001, η² = 0.097; Stroop colour test: F = 3.894, p = 0.010, η² = 0.047) and time-by-group effects (Stroop word test: F = 5.178, p < 0.001, η² = 0.116; Stroop colour test: F = 3.804, p = 0.001, η² = 0.088) were also observed. The changes in the Stroop word test (F = 9.934, p < 0.001, η² = 0.201) and colour test (F = 7.514, p = 0.001, η² = 0.160) from baseline to week 8 were significantly different among the three groups (Fig. 2A, B and Table 2). Post hoc analysis revealed that the CAE group showed significant improvement in the Stroop word test (vs AE group, p = 0.009; vs control group, p < 0.001) and Stroop colour test (vs AE group, p = 0.033; vs control group, p = 0.001) from baseline to week 8. However, no significant difference was found between the AE and control groups in the change of the Stroop word test or Stroop colour test from baseline to week 8. The changes in the Stroop word test (F = 7.445, p = 0.001, η² = 0.159) and colour test (F = 7.004, p = 0.002, η² = 0.151) from baseline to week 12 were significantly different among the three groups (Fig. 2A, B). Post hoc analysis revealed that the CAE group showed significant improvement in the Stroop word test (vs AE group, p = 0.038; vs control group, p = 0.001) and Stroop colour test (vs AE group, p = 0.007; vs control group, p = 0.003) from baseline to week 12. There was no significant
compared with the control group. AE aerobic exercise, CAE CCRT combined with aerobic exercise.

The AE group had a more significant increase in serum BDNF than the control group (p < 0.001, η² = 0.167) at week 8. The changes in serum BDNF from baseline to week 8 were significantly different among the three groups (F = 22.813, p < 0.001, η² = 0.366) as well as a statistically significant time-by-group effect (F = 6.402, p = 0.018, η² = 0.096) (Fig. 3B and Table 2). Post hoc analysis revealed that the CAE group showed significant improvement in PANSS negative scores than the control group (p = 0.015). Neither the CAE group nor the control group showed a significant difference when compared with the AE group. Meanwhile, no significant difference was found among the three groups in terms of change in serum BDNF at weeks 4 and 12 (Fig. 1C).

Other secondary outcomes. There was a statistically significant difference in serum BDNF among the three groups (F = 19.564, p < 0.001, η² = 0.331). A statistically significant time effect (F = 40.633, p < 0.001, η² = 0.340) as well as a statistically significant time-by-group effect (F = 8.589, p < 0.001, η² = 0.179) were also observed. The changes in serum BDNF (F = 22.813, p < 0.001, η² = 0.366) from baseline to week 8 were significantly different among the three groups (Fig. 1C and Table 2). Post hoc analysis revealed that the CAE group (p < 0.001) and AE group (p < 0.001) showed significantly increased serum BDNF at week 8 than the control group, and no significant difference was found between the CAE and AE groups in terms of change in serum BDNF at week 8. The changes in serum BDNF from baseline to week 4 (F = 6.564, p = 0.002, η² = 0.142) and from baseline to week 12 (F = 3.753, p = 0.028, η² = 0.087) were significantly different among the three groups (Fig. 1C). Post hoc analysis revealed that the CAE group showed significantly increased serum BDNF at week 4 (p < 0.003) and week 12 (p < 0.026) than the control group. The AE group had a more significant increase in serum BDNF than the control group (p < 0.036) at week 4. No significant difference was found between the CAE and AE groups in terms of change in serum BDNF at weeks 4 and 12 (Fig. 1C).

Correlations between cognitive performance and other secondary outcomes. Changes in PANSS negative scores were negatively correlated with some changes in cognitive performance (TMT-A: r = 0.490, p < 0.001; SCT: r = -0.533, p < 0.001; Stroop word test: r = -0.349, p = 0.001; Stroop colour test: r = -0.443, p < 0.001). We did not find any significant correlations between changes in other PANSS scores and cognitive performance changes. No significant relationships were found between changes in serum BDNF levels and cognitive performance changes.

Safety outcomes. None of the participants reported serious adverse events. Adverse effects reported during the intervention were mild to moderate and included headache, dizziness, and fatigue.

Table 2. Changes of outcomes in three groups after 8 weeks of intervention (n = 82).

| Outcome                      | Control subjects (n = 31) | CAE subjects (n = 26) | AE subjects (n = 25) | F value | df | p value | η² value | Group difference     |
|------------------------------|---------------------------|-----------------------|----------------------|---------|----|---------|----------|----------------------|
| Speed of processing          |                           |                       |                      |         |    |         |          |                      |
| Δ Trail Making Test-A (s)    | -5.26 (27.18)             | -30.19 (24.88)        | -5.04 (27.19)        | 7.937   | 2  | 0.001  | 0.167    | CAE > Control, AE    |
| Δ Symbol Coding Test         | 3.32 (11.54)              | 16.27 (9.68)          | 4.44 (15.77)         | 8.882   | 2  | <0.001 | 0.184    | CAE > Control, AE    |
| Cognitive flexibility        |                           |                       |                      |         |    |         |          |                      |
| Δ Stroop Word               | 0.65 (17.81)              | 22.61 (14.70)         | 4.48 (24.88)         | 9.934   | 2  | 0.001  | 0.210    | CAE > Control, AE    |
| Δ Stroop Colour             | -0.81 (14.32)             | 13.85 (8.99)          | 2.56 (19.14)         | 7.514   | 2  | 0.001  | 0.160    | CAE > Control, AE    |
| Δ Stroop Colour-Word        | 2.16 (4.50)               | 3.88 (7.11)           | 2.24 (4.82)          | 0.823   | 2  | 0.443  | 0.020    |                      |
| PANSS score                 |                           |                       |                      |         |    |         |          |                      |
| Δ Positive                  | -0.39 (1.99)              | -0.96 (2.29)          | 0.20 (1.85)          | 2.044   | 2  | 0.136  | 0.049    |                      |
| Δ Negative                  | -1.06 (2.37)              | -2.69 (1.83)          | -1.48 (2.22)         | 4.202   | 2  | 0.018  | 0.096    | CAE > Control        |
| Δ General Psychopathology   | -1.81 (3.64)              | -2.23 (3.92)          | -1.92 (4.61)         | 0.081   | 2  | 0.922  | 0.002    |                      |
| Δ Total                     | -3.23 (4.72)              | -5.73 (4.72)          | -2.96 (6.20)         | 2.306   | 2  | 0.106  | 0.055    |                      |
| Δ BDNF in serum (ng/ml)     | 0.86 (4.77)               | 9.14 (4.18)           | 6.09 (5.09)          | 22.81   | 2  | <0.001 | 0.366    | CAE, AE > Control    |

Δ represents the value difference after 8 weeks of intervention. Continuous variables are listed as mean (SD).

BDNF brain-derived neurotrophic factor, AE aerobic exercise, CAE CCRT combined with aerobic exercise.

Fig. 2 Performance of cognitive flexibility (n = 82). A Changes of the Stroop Word Test; B changes of Stroop Colour Test; and C changes of Stroop Colour-Word Test. The results are expressed as mean ± SD. Differences between groups were analysed using two-way ANOVA for repeated measures, and post hoc multiple comparisons at different endpoints were performed using Bonferroni–Dunn test. **p ≤ 0.01, as compared with the control group. AE aerobic exercise, CAE CCRT combined with aerobic exercise.
Bonferroni analysis using a two-way ANOVA for repeated measures, and post hoc multiple comparisons at different endpoints were performed using the Dunn test. *p ≤ 0.05, as compared with the control group. AE aerobic exercise, CAE CCRT combined with aerobic exercise.

were mild and tolerable; participant-reported adverse effects included leg soreness, tiredness, headache, asthenopia, palpitations, and insomnia, and there were no statistically significant differences in terms of side effects across the three groups (Table 3).

**DISCUSSION**

In the present study, we explored the efficacy of a short-term aerobic exercise intervention (administered alone or in combination with CCRT) on cognitive function in patients with chronic schizophrenia. In contrast to the findings of previous similar studies, our results showed that eight weeks of aerobic exercise (administered five times a week) did not statistically significantly improve processing speed or cognitive flexibility in chronic schizophrenia patients. This is consistent with the findings of two randomised controlled trials conducted in patients with dementia or Alzheimer’s disease. Moreover, the results of a prior meta-analysis also showed that, although aerobic exercise rehabilitation statistically significantly improved working memory, social cognition, and attention/vigilance in patients with schizophrenia, it had no statistically significant impact on processing speed, verbal memory, visual memory, reasoning, or problem-solving.

Although the most effective scheme for aerobic exercise training in patients with schizophrenia has not been determined, the pattern of the aerobic exercise intervention applied in this study is very similar to the practice (i.e., standard of care) of exercise rehabilitation in psychiatric departments throughout China. Therefore, our results have significant clinical value. It is also important to note that previous studies have suggested that the duration of aerobic exercise may have a very large impact on cognitive improvement. In addition, we note that the results of this study may have been affected by many factors, such as a short duration of exercise and study-specific differences in exercise patterns and intensities.

This study also found that short-term aerobic exercise combined with CCRT statistically significantly improved negative symptoms, processing speed and partial cognitive flexibility (i.e., without interference) in patients with schizophrenia, and our results also showed that some cognitive improvement was correlated with the remission of negative symptoms. Cognitive impairment is reportedly closely related to negative symptoms in patients with schizophrenia, and their occurrence and progression may have the same biological and pathological mechanisms. Moreover, there are many items about negative symptoms in PANSS involving cognitive flexibility and abstract thinking. Therefore, it is not difficult to comprehend the results of this study. Unfortunately, the CCRT group was evaluated on its own due to limitations in the number of participants included in the present study. However, previous studies have shown that CCRT improves cognitive function in patients with schizophrenia. Therefore, it is impossible to tell whether the improvement in cognitive function seen in this study could be completely attributed to CCRT treatment. Meanwhile, we also found that differences in performance in the Stroop word-colour test were not statistically significant among the three groups, which indicates that the effectiveness of aerobic exercise combined with CCRT on the ability to inhibit cognitive interference and on other complicated cognitive functions may be less than expected.

Our findings also suggest that, although short-term aerobic exercise may not improve cognitive performance, it may increase serum BDNF levels in patients with schizophrenia (as seen in the present study). This finding is somewhat easier to explain, as previous studies have shown that aerobic exercises such as jogging can increase expression levels of serum BDNF by increasing the synthesis and accumulation of neuroactive metabolites (e.g., actin and ketone bodies). However, in the present study, we did not find a significant correlation between the change in serum BDNF level and the improvement of cognitive function. BDNF in serum consists of BDNF bound to platelets and BDNF circulating freely (unbound) in plasma. Since the BDNF stored in platelets is more than 100 times that in plasma, the vast majority of BDNF in serum may not be able to freely pass through the blood–brain barrier to affect the brain function. This may also be one of the explanations for why aerobic exercise was not found to improve cognitive brain function in this study.

Our study also found that the combination of CCRT and aerobic exercise did not statistically significantly increase serum BDNF levels induced by aerobic exercise. There are two possible explanations for this phenomenon. First, previous studies have shown that the effect of cognitive training on serum BDNF levels is relatively limited, and that short-term CCRT is not sufficient to meaningfully increase serum BDNF levels. Second, this finding may be due to the possibility that aerobic exercise might increase serum BDNF to a certain level and that CCRT will not further improve it.
meaningfully increase BDNF expression. Hence, we plan to enrich this evaluation with a comparative evaluation conducted with the enrolment of a healthy control group as well as a group treated with CCRT alone in future research efforts.

This study has some limitations that need to be noted. First, although the sample size of this study was larger than the minimum theoretical sample size, it was still limited. And in consideration of the ability to participate, most of the patients included in this study only suffered from mild to moderate cognitive impairment, which may also limit the promotion of the results. Secondly, we did not set up an intervention evaluating CCRT alone, and hence we could not clarify the independent results. Secondly, we did not set up an intervention evaluating CCRT alone, and hence we could not clarify the independent results. Secondly, we did not set up an intervention evaluating CCRT alone, and hence we could not clarify the independent results. Secondly, we did not set up an intervention evaluating CCRT alone, and hence we could not clarify the independent results. Finally, the short duration of the intervention may limit the recorded effect of aerobic exercise.

CONCLUSIONS
Our study suggests some cognitive performance metrics (i.e., processing speed rather than the ability to inhibit cognitive interference) in patients with schizophrenia may be improved in a short period of time when aerobic exercise is combined with CCRT. Short-term aerobic exercise may increase serum BDNF levels in patients with schizophrenia. However, increased serum BDNF does not necessarily indicate an amelioration of cognitive performance. Our findings, which should be confirmed in future highly powered studies enrolling healthy controls and including patients administered CCRT alone, provide preliminary evidence for improving interventions in schizophrenia patients.

DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Received: 22 June 2022; Accepted: 3 October 2022; Published online: 20 October 2022

REFERENCES
1. Forves, N. F., Carrick, L. A., McIntosh, A. M. & Lawrie, S. M. Working memory in schizophrenia: a meta-analysis. Psychol. Med. 39, 889–905 (2009).
2. Brown, J. W., Rueter, L. E. & Zhang, M. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically. Prog. Neuropsychopharmacol. Biol. Psychiatry 49, 53–62 (2014).
3. Zhu, Y. et al. Functional neuroimaging of social cognition in schizophrenia. Chin. J. Clin. Psychol. 22, 232–239 (2014).
4. Guan, L. L., Du, L. Z. & Ma, H. Burden of schizophrenia: a review. Chin. Ment. Health J. 12, 913–919 (2012).
5. Goldberg, T. E. et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch. Gen. Psychiatry 64, 1115–1122 (2007).
6. Harvey, P. D. Pharmacological cognitive enhancement in schizophrenia. Neuropsychopharmacol. Rev. 19, 324–335 (2009).
7. Huang, Y. C. et al. Effects of aerobic walking on cognitive function in patients with schizophrenia: a randomized controlled trial. J. Psychiatr. Res. 134, 173–180 (2021).
8. Massa, N. et al. The effect of aerobic exercise on physical and cognitive outcomes in a small cohort of outpatients with schizophrenia. Brain Plast., 161–174 (2020).
9. Shimada, T. et al. Aerobic exercise and cognitive functioning in schizophrenia: results of a 1-year follow-up from a randomized controlled trial. Psychiatry Res. 286, 112854 (2020).
10. Firth, J., Cotter, J., Elliott, R., French, P. & Yung, A. R. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol. Med. 45, 1343–1361 (2015).
11. Dauwan, M., Begemann, M. J., Heringa, S. M. & Sommer, I. E. Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis. Schizophr. Bull. 42, 588–599 (2016).
12. Loh, S. Y. et al. Structured walking and institutionalized schizophrenia inmates: a pilot RCT study on quality of life. Glob. J. Health Sci. 8, 238–248 (2016).
13. Ho, R. T. et al. A randomized controlled trial on the psychophysiological effects of physical exercise and Tai-chi in patients with chronic schizophrenia. Schizophr. Res. 171, 42–49 (2016).
14. Laursen, T. M. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr. Res. 131, 101–104 (2011).
15. Pajonk, F. G. et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch. Gen. Psychiatry 67, 133–143 (2010).
16. Svatkova, A. et al. Physical exercise keeps the brain connected: biking increases white matter integrity in patients with schizophrenia and healthy controls. Schizophr. Bull. 41, 869–878 (2015).
17. Kinny, D. et al. Aerobic fitness and body mass index in individuals with schizophrenia: implications for neurocognition and daily functioning. Psychiatry Res. 220, 784–791 (2014).
18. McEwen, S. C. et al. Prefrontal and hippocampal brain volume deficits: role of low physical activity on brain plasticity in first-episode schizophrenia patients. J. Int. Neuropsychol. Soc. 21, 868–887 (2015).
19. Lystad, J. U. et al. Cognitive remediation and occupational outcome in schizophrenia spectrum disorders: a 2 year follow-up study. Schizophr. Res. 185, 122–129 (2017).
20. Liao, L. W., Ding, Y., Wu, X., Zhou, Y. P. & Pan, G. H. A randomized controlled trial of the computerized cognitive remediation therapy to adult schizophrenia. Chin. J. Clin. Psychol. 24, 954–957 (2016).
21. Fan, F., Zou, Y., Tan, Y., Hong, L. E. & Tan, S. Computerized cognitive remediation therapy effects on resting state brain activity and cognition in schizophrenia. Sci. Rep. 7, 4758 (2017).
22. Zheng, F., Zhou, X., Moon, C. & Wang, H. Regulation of brain-derived neurotrophic factor expression in neurons. Int. J. Physiol. Pathophysiol. Pharmacol. 4, 188–200 (2012).
23. Bathina, S. & Das, U. N. Brain-derived neurotrophic factor and its clinical implications. Arch. Med. Sci. 11, 1164–1178 (2015).
24. Tang, X. et al. Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction. BMC Psychiatry 19, 254 (2019).
25. Man, L. et al. Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. Psychiatry Res. 263, 1–6 (2018).
26. Vinogradov, S. et al. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol. Psychiatry 66, 549–553 (2009).
27. Iritani, S., Niiizato, K., Nawa, H., Ikeda, K. & Emson, P. C. Immunohistochemical study of brain-derived neurotrophic factor expression in neurons. J. Physiol. 526, 897–907 (2001).
28. Durany, N. et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenia: a systematic review and meta-analysis. NPJ. Schizophr. Res. 5, 12 (2020).
29. Phillips, C., Baklir, M. A., Srivatsan, M. & Salehi, A. Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. Front. Cell. Neurosci. 8, 170 (2014).
30. Wang, R., Holsinger, R. & Damian, M. Exercise-induced brain-derived neurotrophic factor expression: therapeutic implications for Alzheimer’s dementia. Ageing Res. Rev. 48, 109–121 (2018).
31. Kinny, D. et al. The impact of aerobic exercise on brain-derived neurotrophic factor and neurocognition in individuals with schizophrenia: a single-blind, randomized controlled trial. Schizophr. Bull. 41, 859–868 (2015).
32. Wang, J. Clinical Epidemiology (Shanghai Science and Technology Press, Shanghai, 2009).
33. Chen, K. L. et al. Validation of the Chinese version of montreal cognitive assessment basic for screening mild cognitive impairment. J. Am. Geriatr. Soc. 64, e285–e290 (2016).
34. Zhao, J. P. & Shi, S. X. Chinese Guidelines for Prevention and Treatment of Schizophrenia, the Second Edition (Chinese Medical Multimedia Press, Beijing, 2015).
35. Lin, J. et al. Aerobic exercise and yoga improve neurocognitive function in women with early psychosis. NPJ. Schizophr. 1, 15047 (2015).
36. Erickson, K. I., Voss, M. W. & Prakash, R. S. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci. USA. 108, 3017–3022 (2011).
37. Wykes, T. & Reeder, C. Cognitive Remediation Therapy for Schizophrenia: Theory and Practice (Routledge, London, 2005).
38. He, Y. L. & Zhang, M. Y. The Chinese norm and factors analysis of PANS. Chin. J. Clin. Psychol. 82, 65–69 (2000).
Heisz, J. J. et al. The effects of physical exercise and cognitive training on memory.

Håkansson, K. et al. BDNF responses in healthy older persons to 35 min of physical exercise, cognitive training, and mindfulness: associations with working memory function.

Ihara, K. et al. Serum BDNF levels before and after the development of mood disorders: a case–control study in a population cohort. Transl. Psychiatry 6, e782 (2016).

Nuechterlein, K. H. et al. Enhancing cognitive training through aerobic exercise after a first schizophrenia episode: theoretical conception and pilot study. Schizophr. Bull. 42, 544–552 (2016).

Toots, A. et al. Effects of exercise on cognitive function in older people with dementia: a randomized controlled trial. J. Alzheimers Dis. 60, 323–332 (2017).

Ohman, H. et al. Effects of exercise on cognition: the Finnish Alzheimer disease exercise trial: a randomized, controlled trial. J. Am. Geriatr. Soc. 64, 731–738 (2016).

Firth, J. et al. Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr. Bull. 43, 546–556 (2017).

Erickson, K. I., Weinstein, A. M. & Lopez, O. L. Physical activity, brain plasticity, and Alzheimer’s disease. Arch. Med. Res. 43, 615–621 (2012).

Cancela, J. M., Ayan, C., Varela, S. & Seijo, M. Effects of a long-term aerobic exercise intervention on institutionalized patients with dementia. J. Sci. Med. Sport 19, 293–298 (2016).

Harvey, P. D. Cognitive impairment in schizophrenia: profile, course, and neurobiological determinants. Handb. Clin. Neurol. 106, 433–445 (2012).

Sartory, G., Zorn, C., Groetzing, G. & Windassen, K. Computerized cognitive remediation improves verbal learning and processing speed in schizophrenia. Schizophr. Res. 75, 219–223 (2005).

Scarpina, F. & Tagini, S. The Stroop Color and Word Test. Front. Psychol. 8, 557 (2017).

Heisz, J. J. et al. The effects of physical exercise and cognitive training on memory and neurotrophic factors. J. Cogn. Neurosci. 29, 1895–1907 (2017).

Håkansson, K. et al. BDNF responses in healthy older persons to 35 min of physical exercise, cognitive training, and mindfulness: associations with working memory function. J. Alzheimers Dis. 55, 645–657 (2016).

Walsh, J. J. & Tschakovskiy, M. E. Exercise and circulating BDNF: mechanisms of release and implications for the design of exercise interventions. Appl. Physiol. Nutr. Metab. 43, 1095–1104 (2018).

Karege, F., Schwald, M. & Cisse, M. Postnatal developmental profile of brain derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 328, 261–264 (2002).

ACKNOWLEDGEMENTS

This work was supported by the National Key R&D Program of China (Grant number 2020YFC02005300), and the Science and Technology Program of Wuhu city (Grant number 2018cg11). The authors would like to thank all the participants.

AUTHOR CONTRIBUTIONS

S.H., H.S., W.H. and C.S. conceived and designed the work. Y.D., H.D., X.W., C.X., T.J., Z.L., L.M. and S.H. performed research. X.L. analysed the data. Y.D., S.H., and Z.X. drafted the manuscript. All authors approved the final version for publication.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Hongxian Shen, Wei Hao or Shucai Huang.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022